NCT05262530 2026-04-08
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
Phase 1/2 Terminated
BioNTech SE
Jiangsu HengRui Medicine Co., Ltd.
InxMed (Shanghai) Co., Ltd.
InxMed (Shanghai) Co., Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd.
Novartis
Biohaven Pharmaceuticals, Inc.
Sichuan Huiyu Pharmaceutical Co., Ltd
Salubris Biotherapeutics Inc
Advenchen Laboratories, LLC
Binhui Biopharmaceutical Co., Ltd.
Sanofi